Abstract
Dramatic changes in cell fate occur in development, cancer and reprogramming to the pluripotent state (induced pluripotency). Cells are morphologically defined in vivo by their epithelial or mesenchymal nature. During development, some cells undergo epithelial‐to‐mesenchymal transitions (EMTs) or mesenchymal‐to‐epithelial transitions (METs) as a natural step in the adoption of particular cell fates in most tissues (Acloque et al , 2009). A characteristic of epithelial cancers is an EMT and subsequent invasion of the underlying mesenchyme as a prerequisite for the malignant phenotype (Acloque et al , 2009). Shinya Yamanaka first demonstrated that fibroblasts—typical mesenchymal cells—can be reprogrammed to a pluripotent state (atypical epithelial) by expression of transcription factors associated with pluripotency (Takahashi & Yamanaka, 2006). This discovery was followed by the observation that a MET event occurs early in the reprogramming process (Stadtfeld et al , 2008). > …forced expression of a Yamanaka cocktail including E‐cad is able to drive induced pluripotency, even in the absence of OCT4 As the precise steps and mechanisms of reprogramming to the pluripotent state are mostly obscured in a ‘black box’, it is important to uncover the mechanisms of MET that underlie this process. For decades, proteins such as E‐cadherin (E‐cad) have acted as markers of the epithelial state and are known to be downregulated during an EMT. E‐cad is a transmembrane protein that dimerizes with cadherin molecules on adjacent cells to form adherens junctions. It also interacts with various proteins inside the cell including α‐catenin, β‐catenin and p120, which then interact with the cytoskeleton (Perez‐Moreno et …